Iovance Biotherapeutics Inc [IOVA] stock is trading at $9.76, up 4.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The IOVA shares have gain 5.86% over the last week, with a monthly amount drifted -10.05%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on July 29, 2024, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $10 from $19. Previously, Goldman started tracking the stock with Buy rating on November 20, 2023, and set its price target to $12. On September 18, 2023, Barclays reiterated its Overweight rating and revised its price target to $18 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $17 on May 30, 2023. Piper Sandler upgraded its rating to Overweight for this stock on January 27, 2023, and upped its price target to $14. In a note dated December 09, 2022, Goldman downgraded an Neutral rating on this stock and revised its target price from $20 to $6.
Iovance Biotherapeutics Inc [IOVA] stock has fluctuated between $3.21 and $18.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21.57 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $9.76 at the most recent close of the market. An investor can expect a potential return of 121.0% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Iovance Biotherapeutics Inc [NASDAQ:IOVA] reported sales of 32.77M for the trailing twelve months, which represents a growth of 12969.75%. Gross Profit Margin for this corporation currently stands at -1.07% with Operating Profit Margin at -14.01%, Pretax Profit Margin comes in at -13.61%, and Net Profit Margin reading is -13.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.65 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.33 points at the first support level, and at 8.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.01, and for the 2nd resistance point, it is at 10.26.
Ratios To Look Out For
For context, Iovance Biotherapeutics Inc’s Current Ratio is 5.15. On the other hand, the Quick Ratio is 4.85, and the Cash Ratio is 2.44. Considering the valuation of this stock, the price to sales ratio is 90.40, the price to book ratio is 3.78.
Transactions by insiders
Recent insider trading involved MCPEAK MERRILL A, Director, that happened on Feb 20 ’24 when 0.25 million shares were purchased. Director, Dukes Iain D. completed a deal on Feb 20 ’24 to buy 32000.0 shares. Meanwhile, Director Rothbaum Wayne P. bought 5.0 million shares on Feb 20 ’24.
